52663-90-8

Basic information

• Product Name: 2',3'-Isopropylidene Ribavirin
• Synonyms: 2',3'-Isopropylidene Ribavirin;1-[2,3-O-(1-Methylethylidene)-β-D-ribofuranosyl]-1H-1,2,4-triazole-3-carboxaMide;1-(2,3-O-Isopropyliden-beta-D-ribofuranosyl)-1H-1,2,4-triazol-3-carboxaMid
• CAS NO: 52663-90-8
• Molecular Formula: C₁₁H₁₆N₄O₅
• Molecular Weight: 284.26854
• Product Categories: Bases & Related Reagents;Carbohydrates & Derivatives;Inhibitors;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 52663-90-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 2',3'-Isopropylidene Ribavirin(CAS DataBase Reference)
• NIST Chemistry Reference: 2',3'-Isopropylidene Ribavirin(52663-90-8)
• EPA Substance Registry System: 2',3'-Isopropylidene Ribavirin(52663-90-8)

Safety Data

• Hazardous Substances Data: 52663-90-8(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Syrup

Uses

Protected Ribavirin.

Upstream product

• 67-64-1 acetone 
• 36791-04-5 ribavirin 
• 122-51-0 orthoformic acid triethyl ester 
• 77-76-9 2,2-dimethoxy-propane 
• 79437-71-1 Amino(2,3-O-isopropyliden-D-ribofuranosylhydrazono)essigsaeure-ethylester 
• 79437-74-4 1-(2,3-O-Isopropyliden-β-D-ribofuranosyl)-1H-1,2,4-triazol-3-carbonsaeure-ethylester 

Downstream Products

• 52663-91-9 1-[5,5-(N,N'-diphenyl-N,N'-ethane-1,2-diyl-diamino)-O²,O³-isopropylidene-β-D-5-deoxy-ribofuranosyl]-1H-[1,2,4]triazole-3-carboxylic acid amide 
• 36791-04-5 ribavirin 
• 120615-22-7 1-(5'-O-sulfamoyl-β-D-ribofuranosyl)<1,2,4>triazole-3-carboxamide 
• 1246280-90-9 phosphoric acid ((3aR,4R,6R,6aR)-6-(3-carbamoyl-[1,2,4]-triazol-1-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethyl) ester 2-{[5-cyclopropyl-2-(4-fluorophenyl)-3-methylcarbamoylbenzofuran-6-yl]methanesulfonylamino}ethyl ester 
• 1246280-93-2 C₃₇H₄₁FN₆O₁₂S 

Relevant articles and documents

Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver

Ribavirin is used to treat hepatitis C but causes serious hemolytic anemia. The objective of the study was to develop a ribavirin prodrug to achieve liver-specific drug delivery and to reduce its off-target effect in red blood cells (RBCs). The approach aimed to target the human sodium taurocholate cotransporting polypeptide (NTCP), which is a bile acid transporter predominately expressed in the liver. Six prodrugs with ribavirin conjugation at C-3 or C-24 of the bile acids were synthesized. In vitro uptake studies indicated that all six prodrugs were NTCP substrates. Metabolic studies in vitro indicated that ribavirin-l-Val-glycochenodeoxycholic acid (GCDCA) was able to release ribavirin in the mouse liver S9 fraction. Additionally, in vitro studies showed that ribavirin in RBC was reduced by 16.7-fold from prodrug compared with parent drug incubation. Moreover, almost no prodrug was present in RBC. In vivo study in mice also showed that ribavirin-l-Val-GCDCA could provide almost the same ribavirin exposure in the liver as ribavirin administration, but with about 1.8-fold less exposure of ribavirin in RBC, plasma, and kidney. Overall, the study suggested that ribavirin-l-Val-GCDCA has the potential to achieve ribavirin-specific liver delivery.

Ribavirin semi-antigen and artificial antigen and its preparation method and application (by machine translation)

The invention relates to ribavirin semi-antigen and artificial antigen and its preparation method and application. The ribavirin semi-antigen having a structure of formula (I) or formula (II) as shown: The ribavirin artificial antigen is represented by t

Design and synthesis of HCV agents with sequential triple inhibitory potentials

The union of HCV-796, a potent selective HCV NS5B polymerase inhibitor, and Ribavirin, a molecule with activities against a wide spectrum of viruses, resulted in a class of new anti-HCV agents with a sequential triple inhibitory mechanism.